IN2014CN04119A - - Google Patents
Info
- Publication number
- IN2014CN04119A IN2014CN04119A IN4119CHN2014A IN2014CN04119A IN 2014CN04119 A IN2014CN04119 A IN 2014CN04119A IN 4119CHN2014 A IN4119CHN2014 A IN 4119CHN2014A IN 2014CN04119 A IN2014CN04119 A IN 2014CN04119A
- Authority
- IN
- India
- Prior art keywords
- glimepiride
- atorvastatin
- pharmaceutically acceptable
- acceptable salts
- aspects
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN4119CHN2014 IN2014CN04119A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2011-11-15 | 2012-11-14 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3920CH2011 | 2011-11-15 | ||
| US201261582566P | 2012-01-03 | 2012-01-03 | |
| IN4119CHN2014 IN2014CN04119A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2011-11-15 | 2012-11-14 | |
| PCT/IB2012/002860 WO2013072770A2 (en) | 2011-11-15 | 2012-11-14 | Pharmaceutical formulations comprising atorvastatin and glimepiride |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014CN04119A true IN2014CN04119A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-07-10 |
Family
ID=48430284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN4119CHN2014 IN2014CN04119A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2011-11-15 | 2012-11-14 |
Country Status (5)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230181532A1 (en) * | 2020-05-18 | 2023-06-15 | Board Of Regents, The University Of Texas System | Granules for 3d printing technology |
| CN112618499B (zh) * | 2020-12-24 | 2022-09-30 | 石药集团欧意药业有限公司 | 一种格列美脲分散片剂组合物及其制备方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2951135A1 (de) | 1979-12-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
| DE3320582A1 (de) | 1983-06-08 | 1984-12-13 | Dr. Karl Thomae Gmbh, 7950 Biberach | Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung |
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| DE69324504T2 (de) | 1993-01-19 | 1999-08-26 | Warner-Lambert Co. | Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren |
| CZ294108B6 (cs) | 1995-07-17 | 2004-10-13 | Warner@Lambertácompany | Krystalická forma I hydrátu atorvastatinuŹ tj@ semivápenaté soli kyseliny [R@}RgŹRgB]@}@fluorfenylB@betaŹdelta@dihydroxy@Q@}�@methylethylB@fenyl[}fenylaminoBkarbonyl]@�H@pyrrol@�@heptanové |
| SI20109A (sl) | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
| GB0001662D0 (en) | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
| EP1274401B2 (en) | 2000-04-10 | 2014-08-13 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
| AU2000250960A1 (en) | 2000-06-09 | 2001-12-17 | Lek Pharmaceuticals D.D. | Stable pharmaceutical product and formulation |
| ES2215050T3 (es) | 2000-06-09 | 2004-10-01 | Lek Pharmaceutical And Chemical Co. D.D. | Composicion estabilizada farmaceuticamente eficaz y formulacion farmaceutica que la comprende. |
| AR030379A1 (es) | 2000-08-22 | 2003-08-20 | Novartis Ag | Combinaciones |
| US7074818B2 (en) | 2001-07-30 | 2006-07-11 | Dr. Reddy's Laboratories Limited | Crystalline forms VI and VII of Atorvastatin calcium |
| CA2475722A1 (en) | 2002-02-14 | 2003-08-21 | Romi Barat Singh | Formulations of atorvastatin stabilized with alkali metal additions |
| US20030171407A1 (en) | 2002-03-07 | 2003-09-11 | Upsher-Smith Laboratories, Inc. | Composition for reducing blood glucose and cholesterol |
| CA2385529A1 (en) | 2002-05-21 | 2003-11-21 | Bernard Charles Sherman | Stable dosage forms comprising atorvastatin calcium |
| SI21302A (sl) | 2002-10-11 | 2004-04-30 | LEK farmacevtska dru�ba d.d. | Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino |
| US20040147564A1 (en) | 2003-01-29 | 2004-07-29 | Rao Vinay U. | Combinations of glimepiride and the thiazolidinedione for treatment of diabetes |
| SI21400A (sl) | 2003-02-12 | 2004-08-31 | LEK farmacevtska družba d.d. | Stabilna farmacevtska oblika z inhibitorjem HMG-CoA reduktaze |
| CA2465565A1 (en) | 2003-06-12 | 2004-12-12 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| WO2006006021A2 (en) | 2004-06-28 | 2006-01-19 | Glenmark Pharmaceuticals Limited | Stabilized pharmaceutical compositions of preferably a statin |
| US20080009540A1 (en) | 2004-09-30 | 2008-01-10 | Srinivasulu Gudipati | Amorphous Atorvastatin Calcium |
| EP1849830B1 (en) | 2005-01-28 | 2012-02-29 | Takeda Pharmaceutical Company Limited | Finely divided composition containing poorly water soluble substance |
| US20100034885A1 (en) | 2005-06-10 | 2010-02-11 | Combino Pharm, S.L. | Formulations containing glimepiride and/or its salts |
| CN101103990A (zh) * | 2006-07-14 | 2008-01-16 | 北京华安佛医药研究中心有限公司 | 含有磺脲类降糖药物和他汀类降脂药物的组合物 |
| AU2007300071A1 (en) | 2006-09-27 | 2008-04-03 | Dr. Reddy's Laboratories Ltd. | Atorvastatin pharmaceutical compositions |
| WO2009140341A2 (en) * | 2008-05-13 | 2009-11-19 | Dr. Reddy's Laboratories Ltd. | Atorvastatin compositions |
-
2012
- 2012-11-14 IN IN4119CHN2014 patent/IN2014CN04119A/en unknown
- 2012-11-14 EP EP12826534.5A patent/EP2779999A2/en not_active Withdrawn
- 2012-11-14 WO PCT/IB2012/002860 patent/WO2013072770A2/en active Application Filing
- 2012-11-14 RU RU2014124118/15A patent/RU2014124118A/ru not_active Application Discontinuation
-
2014
- 2014-05-22 ZA ZA2014/03735A patent/ZA201403735B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013072770A3 (en) | 2013-10-24 |
| RU2014124118A (ru) | 2015-12-27 |
| EP2779999A2 (en) | 2014-09-24 |
| WO2013072770A2 (en) | 2013-05-23 |
| ZA201403735B (en) | 2015-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20140567A (es) | Formulaciones y métodos para la administración vaginal de antiprogestinas | |
| SG10201810985XA (en) | Tofacitinib oral sustained release dosage forms | |
| AR081678A1 (es) | Metodos y composiciones para administracion intratecal de arisulfatasa a | |
| NZ702663A (en) | Nuclear transport modulators and uses thereof | |
| MX2014009757A (es) | Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia. | |
| IN2012DN06720A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| UA109010C2 (en) | Morpholino pyrividines and their use in therapy | |
| MX351584B (es) | Formulacion farmaceutica acuosa de tapentadol para administracion oral. | |
| MX2013001677A (es) | Formulaciones estables de linaclotida. | |
| UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
| CY1118032T1 (el) | Διεργασιες για την εμπορικη παρασκευη φαρμακευτικα δραστικου παραγοντα | |
| MY159492A (en) | Solid pharmaceutical formulation with delayed release | |
| PH12013500784A1 (en) | Pharmaceutical compositions comprising nano size droplets of skin whitening agents | |
| MX347105B (es) | Composiciones farmaceuticas que comprenden hidromorfona y naloxona. | |
| EA201201109A1 (ru) | Прасугрель в тонкоизмельченной кристаллической форме и фармацевтическая композиция, содержащая его | |
| ZA201500362B (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | |
| MX2016001422A (es) | Composicion farmaceutica de fingolimod. | |
| EP2583972A4 (en) | THERAPEUTIC FOR INFLAMMATORY DISEASES WITH ADENOSINE N1-OXIDE AS AN ACTIVE SUBSTANCE | |
| CO6592109A2 (es) | Nueva forma cristalina de un derivado de ciclopropilbenzamida | |
| WO2012064304A3 (en) | Combinations comprising montelukast | |
| JO3587B1 (ar) | أشكال جرعات بينداموستين عن طريق الفم | |
| EA201490573A1 (ru) | Соединение бензотиазолона | |
| BR112014004737A2 (pt) | composto de composição de cloridrato de ambroxol e método de preparação do composto | |
| IN2014CN04119A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| WO2011093831A3 (en) | Effervescent formulations comprising cefprozil as active agent |